Nationwide Fund Advisors maintained its stake in Insys Therapeutics, Inc. (NASDAQ:INSY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,506 shares of the specialty pharmaceutical company’s stock at the end of the 2nd quarter. Nationwide Fund Advisors’ holdings in Insys Therapeutics were worth $171,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. Geode Capital Management LLC grew its position in Insys Therapeutics by 9.7% during the first quarter. Geode Capital Management LLC now owns 305,044 shares of the specialty pharmaceutical company’s stock worth $3,206,000 after buying an additional 26,913 shares in the last quarter. Strs Ohio grew its position in Insys Therapeutics by 40.0% during the second quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock worth $2,213,000 after buying an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp grew its position in Insys Therapeutics by 1.2% during the second quarter. Bank of New York Mellon Corp now owns 156,471 shares of the specialty pharmaceutical company’s stock worth $1,980,000 after buying an additional 1,876 shares in the last quarter. Alliancebernstein L.P. grew its position in Insys Therapeutics by 128.6% during the second quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock worth $1,782,000 after buying an additional 79,220 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Insys Therapeutics by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock worth $1,012,000 after buying an additional 475 shares in the last quarter. 25.23% of the stock is currently owned by institutional investors and hedge funds.

Shares of Insys Therapeutics, Inc. (INSY) opened at $5.29 on Friday. Insys Therapeutics, Inc. has a twelve month low of $4.10 and a twelve month high of $15.02.

WARNING: “Nationwide Fund Advisors Continues to Hold Stake in Insys Therapeutics, Inc. (INSY)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/17/nationwide-fund-advisors-continues-to-hold-stake-in-insys-therapeutics-inc-insy.html.

A number of equities research analysts recently issued reports on INSY shares. Zacks Investment Research raised Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research report on Tuesday, October 24th. Royal Bank Of Canada set a $8.00 price target on Insys Therapeutics and gave the stock a “buy” rating in a research report on Friday, October 27th. Jefferies Group LLC reduced their price target on Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. TheStreet downgraded Insys Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, August 21st. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Insys Therapeutics has an average rating of “Hold” and a consensus target price of $9.38.

Insys Therapeutics Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.